How to manage thrombosis in myeloproliferative neoplasms

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 654-658

  Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

chronic myeloproliferative neoplasms; essential thrombocythemia; polycythemia vera; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; CHLORAMBUCIL; CYTOTOXIC AGENT; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; PEGINTERFERON ALPHA2A; PHOSPHORUS; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; DRUG MECHANISM; GENE MUTATION; HIGH RISK POPULATION; HUMAN; LEUKOCYTOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; VEIN THROMBOSIS;

HUMANS; MYELOPROLIFERATIVE DISORDERS; THROMBOSIS;

EID: 80054118403     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bb867     Document Type: Review

References (37)

1. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89:215-232. (Pubitemid 38796497)
2. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Haematol 2005; 130:174-195. (Pubitemid 41602518)
3. Barbui T, Barosi G, Biergagard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29:761-770.
4. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23:2224-2232. (Pubitemid 46218714)
5. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008; 22:1494-1502.
6. Di Nisio M, Barbui T, Di Gennaro L, et al. The hematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136:249-259. (Pubitemid 46020752)
7. Carobbio A, Finazzi G, Antonioli A, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112:3135-3137.
8. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310-2313. (Pubitemid 46425868)
9. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2009; 115:778-782.
10. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-2452. (Pubitemid 46425887)
11. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26:2732-2736.
12. Kundranda MN, Maiti B, Iqbal N, et al. The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPDs). Blood 2008; 112:abstract 2803.
13. Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009; 115:5740-5745.
14. Passamonti F, Rumi E, Pascutto C, et al. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7:1587-1589.
15. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114:759-763.
16. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22:2020-2028.
17. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96:315-318.
18. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22:1299-1307.
19. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009; 124:409-417.
20. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia. Blood 2008; 112:844-847.
21. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112:141-149.
22. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009; 27:2991-2999.
23. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23:132-143.
24. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2:1219-1222. (Pubitemid 9071903)
25. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-124. (Pubitemid 38056222)
26. Harrison C, Barbui T. Aspirin in low-risk essential thrombocythemia, not so simple after all? Leuk Res 2011; 35:286-289.
27. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116:1205-1210.
28. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105:2664-2670. (Pubitemid 40446255)
29. Bjö rkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29:2410-2415.
30. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 1995; 332:1132-1136.
31. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polimorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4:2593-2598. (Pubitemid 44741554)
32. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108:2037-2040. (Pubitemid 44395018)
33. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107:451-458. (Pubitemid 44107203)
34. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112:3065-3072.
35. Samuelsson J, Mutschler M, Birgegard G, et al. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006; 91:1281-1282. (Pubitemid 44408447)
36. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27:5418-5424.
37. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33-45. (Pubitemid 41007805)